ioGenetics has constructed and expressed over a hundred different fusion peptides.
Anticryptosporidial Therapeutics
The company's lead product group comprises anticryptosporidial proteins which are effective when administered orally in several lab animal models and in calves. Efficacy has been shown against Cryptosporidium parvum and C. hominis. Work is ongoing to develop these both as veterinary and human pharma products.
Work in progress
Work is in progress on product groups which target Staphylococcus aureus (including MRSA) and influenza viruses among other targets.
Peptide epitope libraries have been compiled for several genera of bacteria and protozoa and more are in progress.
Visit our site again soon for more specifics about our pipeline.
